Alfacalcidol -Important Medicines Safety Alert
Specialist endocrinology teams have identified a number of patients with hypoparathyroidism experiencing significant fluctuations in calcium levels, including severe hypocalcaemia requiring emergency treatment. Investigation has identified cases where patients prescribed Alfacalcidol have received food supplement preparations rather than licensed medicinal products.
Patients with hypoparathyroidism require precise and consistent dosing of Alfacalcidol to maintain calcium control. Licensed medicinal products are manufactured to regulated pharmaceutical standards and contain a guaranteed amount of active ingredient. In contrast, food supplement preparations are not licensed medicines and may not provide the same assurance of potency, consistency, or quality.
Actions required
- When dispensing Alfacalcidol, ensure that a licensed medicinal product is supplied.
- Food supplement preparations of Alfacalcidol should not be substituted for licensed medicinal products.
- Patients with hypoparathyroidism who report recent changes in Alfacalcidol brand or appearance should be reviewed promptly if there are concerns regarding calcium control.
If you have concerns regarding patients who may have received an unlicensed food supplement preparation in place of a licensed medicinal product, please seek specialist endocrinology advice where appropriate.
How to identify a food supplement
Please check products carefully as food supplement preparations can appear similar to licensed medicines:
- The box will not have “POM” (Prescription Only Medicine) stated on the packaging if it is a food supplement.
- Food supplements will often have the wording “Food Supplement” on the outer packaging and/or within the Patient Information Leaflet (PIL).
- When searching for the product in the BNF, the legal category will state “Not Applicable”, or in the BNF mobile application the medicinal form will not display “POM”.



